These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16532260)

  • 1. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K
    Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
    Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
    Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.
    Matsui K; Kamijo-Ikemori A; Imai N; Sugaya T; Yasuda T; Tatsunami S; Toyama T; Shimizu M; Furuichi K; Wada T; Shibagaki Y; Kimura K
    Clin Exp Nephrol; 2016 Apr; 20(2):195-203. PubMed ID: 26189083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.
    Kamijo-Ikemori A; Sugaya T; Yoshida M; Hoshino S; Akatsu S; Yamazaki S; Kimura K; Shibagaki Y
    Clin Chem Lab Med; 2016 Oct; 54(10):1645-54. PubMed ID: 26943609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary liver type fatty acid binding protein in diabetic nephropathy.
    Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Matsui K; Yokoyama T; Yasuda T; Hirata K; Kimura K
    Clin Chim Acta; 2013 Sep; 424():104-8. PubMed ID: 23727660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial.
    Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Kimura K
    J Lab Clin Med; 2005 Mar; 145(3):125-33. PubMed ID: 15871303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [L-type fatty acid binding protein (L-FABP) and kidney disease].
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
    Mou S; Wang Q; Li J; Shi B; Ni Z
    Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2'-deoxyguanosine in forensic autopsy cases.
    Kashiwagi M; Sugimura T; Matsusue A; Hara K; Waters B; Kubo S
    Leg Med (Tokyo); 2013 May; 15(3):140-4. PubMed ID: 23273867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Worsening Renal Function in Patients With Acute Heart Failure.
    Okubo Y; Sairaku A; Morishima N; Ogi H; Matsumoto T; Kinoshita H; Kihara Y
    J Card Fail; 2018 Aug; 24(8):520-524. PubMed ID: 30026130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.
    Kamijo A; Kimura K; Sugaya T; Yamanouchi M; Hikawa A; Hirano N; Hirata Y; Goto A; Omata M
    J Lab Clin Med; 2004 Jan; 143(1):23-30. PubMed ID: 14749682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
    BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary fatty acid binding protein in renal disease.
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
    Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
    Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
    PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine liver fatty acid binding protein and chronic kidney disease progression.
    Khatir DS; Bendtsen MD; Birn H; Nørregaard R; Ivarsen P; Jespersen B; Buus NH
    Scand J Clin Lab Invest; 2017 Nov; 77(7):549-554. PubMed ID: 28745927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.
    Manabe K; Kamihata H; Motohiro M; Senoo T; Yoshida S; Iwasaka T
    Eur J Clin Invest; 2012 May; 42(5):557-63. PubMed ID: 22070248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
    Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
    Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.